Granted Patent
B2
US 12,201,676 · App. 15/283,778 · Granted Jan 21, 2025
Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome
Assignee:
DR HEALTHCARE ESPAÑA, S.L.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A composition includes diamine oxidase for use in prevention or treatment of symptoms and disorders caused by fibromyalgia or chronic fatigue syndrome.
Claims (11)
1. A method of treating a patient,
wherein the patient presents the symptoms and disorders caused by fibromyalgia or chronic fatigue syndrome,
wherein the symptoms and disorders comprise fatigue, sleep disorders and musculoskeletal pain,
wherein the method comprises administering to said patient a composition comprising diamine oxidase (DAO), and
wherein the administering results in a treatment of the patient, wherein the treatment is characterized by an effect selected from the group consisting of relief from the symptoms and disorders of fibromyalgia or chronic fatigue syndrome, reduction of any direct or indirect pathology of fibromyalgia or chronic fatigue syndrome, reduction of the speed of progression of fibromyalgia or chronic fatigue syndrome, improvement of fibromyalgia or chronic fatigue syndrome, prevention of recurrence of fibromyalgia or chronic fatigue syndrome, or combinations thereof.
2. The method according to claim 1 , wherein said DAO is administered orally in the form of tablets, capsules or sachets.
3. The method according to claim 1 , wherein said DAO is administered at a dose of between 0.1 and 50 mg.
4. The method according to claim 1 , wherein said composition also contains caffeine.
5. The method according to claim 1 , wherein said composition also contains caffeine which is administered at a dose of between 1 and 100 mg.
6. The method according to claim 1 , wherein said DAO has a gastric protection.
7. The method according to claim 1 , wherein said DAO is used in free form, in powder, lyophilised powder, microcapsules, nanocapsules or liposomes.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 10, 2016
From: DUELO RIU, CARLOS; DUELO RIU, JUAN JOSÉ
To: DR HEALTHCARE ESPAÑA, S.L.
Reel/Frame 040298/0007 →
Priority Claims (1)
ES ES201130383
· Mar 18, 2011
· national
Continuity (2)
Continuation In Part
14005020
References Cited (80)
US 3721733A
· Van Leeuwen
· 1973
[cited by applicant]
US 4703045A
· Guinot
· 1987
[cited by applicant]
US 4725540A
· Underberg et al.
· 1988
[cited by applicant]
US 4851243A
· Andersen et al.
· 1989
[cited by applicant]
US 8003343B2
· Missbichler et al.
· 2011
[cited by applicant]
US 9795654B2
· Duelo Riu et al.
· 2017
[cited by examiner]
US 20060002913A1
· Gehlsen
· 2006
[cited by applicant]
US 20080193491A1
· Missbichler et al.
· 2008
[cited by applicant]
US 20080306066A1
· Carruthers et al.
· 2008
[cited by applicant]
US 20110236491A1
· Chantalat et al.
· 2011
[cited by applicant]
US 20130344136A1
· Duelo Riu et al.
· 2013
[cited by applicant]
US 20130344137A1
· Duelo Riu et al.
· 2013
[cited by applicant]
US 20140004179A1
· Duelo Riu et al.
· 2014
[cited by applicant]
US 20140004180A1
· Duelo Riu et al.
· 2014
[cited by applicant]
US 20160024481A1
· Duelo Riu et al.
· 2016
[cited by applicant]
EP 0132674A2
· 1985
[cited by applicant]
EP 0865737A2
· 1998
[cited by applicant]
EP 1277477A2
· 2003
[cited by applicant]
EP 2020446A1
· 2009
[cited by applicant]
ES 2132037A1
· 1999
[cited by applicant]
ES 2387973B1
· 2013
[cited by applicant]
ES 2388395B1
· 2013
[cited by applicant]
ES 2388515B1
· 2013
[cited by applicant]
FR 2101095A1
· 1972
[cited by applicant]
FR 2215944A1
· 1974
[cited by applicant]
GB 1313318A
· 1973
[cited by applicant]
WO WO9207475A1
· 1992
[cited by applicant]
WO WO9631130A2
· 1996
[cited by applicant]
WO WO0243745A2
· 2002
[cited by applicant]
WO WO200243745A2
· 2002
[cited by applicant]
WO WO03035000A2
· 2003
[cited by applicant]
WO WO2006003213A1
· 2006
[cited by applicant]
WO WO2007144153A2
· 2007
[cited by applicant]
WO WO2008113871A1
· 2008
[cited by applicant]
WO WO2012127381A1
· 2012
[cited by applicant]
WO WO2012127391A1
· 2012
[cited by applicant]
WO WO2012127392A1
· 2012
[cited by applicant]
Taylor, “Quality of life and symptom severity for individuals with chronic fatigue syndrome: Findings from a randomized clinical trial,” American Journal of Occupational Therapy, vol. 58, No. 1, pp. 35-43 (Year: 2004).
[cited by examiner]
Buskila et al, “Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome,” Arthritis Research & Therapy, vol. 8, No. 5, 218, pp. 1-5 (Year: 2006).
[cited by examiner]
Shin et al, “Inhibitory effect of anaphylactic shock by caffeine in rats,” International Journal of Immunopharmacology, vol. 22, No. 6, pp. 411-418 (Year: 2000).
[cited by examiner]
White et al, “Classification, Epidemiology, and Natural History of Fibromyalgia,” Current Pain and Headache Reports, vol. 5, No. 4, pp. 320-329 (Year: 2001).
[cited by examiner]
Cozza, S.J. et al.; “Treatment of Children and Adolescents”; Clinical Psychiatric Treatment, vol. II, Chapter XXXIII; 2004; p. 1408.
[cited by applicant]
Tallgren, Antti, “International Search Report” prepared for PCT/IB2012/051276, as mailed Jun. 9, 2012, 6 pages.
[cited by applicant]
Maintz, Laura, et al., “Histamine and histamine intolerance”, The American Journal of Clinical Nutrition, American Society for Nutrition, U.S., May 1, 2007, vol. 85, No. 5, pp. 1185-1196.
[cited by applicant]
Tallgren, Antti,“International Search Report”, prepared for PCT/IB2012/051253 as mailed Jul. 6, 2012, 4 pages.
[cited by applicant]
Tallgren, Antti, “International Search Report” for PCT/IB2012/051252, as mailed Jul. 6, 2012, 4 pages.
[cited by applicant]
Zimmerman, “Pathophysiological Mechanisms of Fibromyalgia,” The Clinical Journal of Pain, vol. 7, No. 1, pp. S8-S15, (1991).
[cited by applicant]
Meggs, “Neurogenic Switching: a Hypothesis for a Mechanism for Shifting the Site of Inflammation in Allergy and Chemical Sensitivity Environmental Health Perspectives,” vol. 103, No. 1, pp. 54-56, (1995).
[cited by applicant]
Arnold et al., “Family Study of Fibromyalgia,” Arthritis & Rheumatism, vol. 50, No. 3, pp. 944-952, (2004).
[cited by applicant]
Van Ittersum et al., “Illness Perceptions in Patients with Fibromyalgia,” Patient Education and Counseling, vol. 74, Issue 1, pp. 53-60, (2009).
[cited by applicant]
Mason et al., “Evaluation of a Multimodal Treatment Program for Fibromyalgia,” Journal of Behavioral Medicine, vol. 21, No. 2, pp. 163-178, (1998).
[cited by applicant]
Vaerøy et al., “Treatment of Fibromyalgia (Fibrositis Syndrome): a Parallel Double Blind Trial with Carisoprodol, Paracetamol and Caffeine (Somadril Comp®) Versus Placebo,” Clinical Rheumatology, vol. 8, Issue 2, pp. 24…
[cited by applicant]
Biofunctionalism.com, “Fibromyalgia and DAO Deficiency,” http://biofunctionalism.com/fibromyalgia-and-dao-deficiency/, Oct. 11, 2010, 3 pages.
[cited by applicant]
Dechene, L.; “Chronic Fatigue Syndrome: Influence of Histamine, Hormones and Electrolytes”; Medical Hypothesis, vol. 40, No. 1; Jul. 1992; pp. 55-60.
[cited by applicant]
John, Joshi, et al.; “Caffeine Promotes Glutamate and Histamine Release in the Posterior Hypothalamus”; Am J Physiol Regul Integr Comp Physiol, vol. 307; Jul. 16, 2014; pp. R704-R710.
[cited by applicant]
Grozman, M., et al.; “Change in Serum Histamine Indexes in Calves under the Influence of Caffeine”; Trudy Moldavskoi Ovoshche-kartofel'noi Orositel'noi Opytnoi Stantsii (1971), 7, 277-80 (Abstract only).
[cited by applicant]
Roth, J.A., et al.; “The Effect of Vagotomy and Atropine upon Caffeine Stimulation of Gastric Secretion”; Gastroenterology (1945), 5, 129-34 (Abstract only).
[cited by applicant]
Stoltner, Anton, “International Search Report” for PCT/IB2012/051275, as mailed May 21, 2012, 3 pages.
[cited by applicant]
Shimoda, et al., “Investigation of the mechanism of alcohol-induced bronchial asthma”, Journal of Allergy and Clinical Immunology, Mosby, Inc, US, Jan. 1, 1996, vol. 97, No. 1, pp. 74-84.
[cited by applicant]
Linneberg, A., et al., “Genetic determinants of both ethanol and acetaldehyde metabolism influence alcohol hypersensitivity and drinking behaviour among Scandinavians”, Clinical & Experimental Allergy, Wiley Interscienc…
[cited by applicant]
Pittler, Max H., et al.; “Interventions for Preventing or Treating Alcohol Hangover: Systematic Review of Randomised Controlled Trials”; BJM, vol. 331; Dec. 22, 2005; 4 pages.
[cited by applicant]
Stephens, Richard, et al.; “A Review of the Literature on the Cognitive Effects of Alcohol Hangover”; Alcohol & Alcoholism, vol. 43, No. 2; Jan. 31, 2008; pp. 163-170.
[cited by applicant]
Swift, Robert, et al.; “Alcohol Hangover: Mechanisms and Mediators”; Alcohol Health & Research World, vol. 22, No. 1; Jan. 1998; pp. 54-60.
[cited by applicant]
Stoltner, Anton, “International Search Report,” prepared for PCT/IB2013/053068, as mailed Aug. 13, 2013, four pages.
[cited by applicant]
Wigal, Sharon B., “Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults,” CNS Drugs 2009; 23 Suppl. 1, 2009, pp. 21-31.
[cited by applicant]
Brown, Ronald T. et al., “Treatment of Attention-Deficit/Hyperactivity Disorder: Overview of the Evidence,” Pediatrics vol. 115, No. 6, Jun. 6, 2005, pp. e749-e757.
[cited by applicant]
Montañés-Rada, F., et al., “Fármacos para el trastorno por déficit de atención/hiperactividad,” Rev Neurol 2009; 48(9), Mar. 31, 2009, pp. 469-481.
[cited by applicant]
Howard, Harry R.; “Agents for Attention-Deficit Hyperactivity Disorder—An Update”; Expert Opinion on Therapeutic Patents, Informa Healthcare, GB; vol. 14, No. 7; Jul. 1, 2004; pp. 983-1008.
[cited by applicant]
Stevenson, Jim, et al.; “The Role of Histamine Degradation Gene Polymorphisms in Moderating the Effects of Food Additives on Children's ADHD Symptoms”; Am J Psychiatry 167:9; Sep. 2010; pp. 1108-1115.
[cited by applicant]
Bodmer, S., et al.; “Biogenic Amines in Foods: Histamines and Food Processing”; Inflammation Research, vol. 48, No. 6; Jun. 1999; pp. 296-300.
[cited by applicant]
National Fibromyalgia & Chronic Pain Association, “What is Fibromyalgia?” National Fibromyalgia & Chronic Pain Association, “What is Fibromyalgia?,” URL: <https://www.fmcpaware.org/fibromyalgia/about-fm.html>, Retrieved…
[cited by applicant]
Work Wellness and Disability Prevention Institute (WWDPI); “Fibromyalgia”; https://www.wwdpi.org/ChronicDisease/HealthTopics/MusculoskeletalDisorders/Pages/Fibromyalgia.aspx; last updated Jun. 12, 2018; 7 pages.
[cited by applicant]
Centers for Disease Control and Prevention; “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome”; https://www.cdc.gov/me-cfs/index.html; last updated Jun. 29, 2018; 4 pages.
[cited by applicant]
WebMD, Migraine & Headaches Center: Physician Reviewed Headache Information, https://www.webmd.com/migraines-headaches/default.htm. Retrieved: Nov. 15, 18; 5 pages.
[cited by applicant]
Ibuprofen—NHS, https://www.nhs.uk/conditions/ibuprofen/. Last reviewed: May 17, 2016; Retrieved: Nov. 15, 2018, 9 pages.
[cited by applicant]
Migraine—definition of migraine by The Free Dictionary, https://www.thefreedicitionary.com/migraine. Retrieved: Nov. 15, 2018; 4 pages.
[cited by applicant]
Silent Migraine, https://migraine.com/migraine-types/silent-migraine/ Written by Otesa Miles, Last reviewed: Aug. 2014, Retrieved: Nov. 15, 2018; 5 pages.
[cited by applicant]